- Merck (NYSE:MRK) strengthens its oncology pipeline, as it has agreed to acquire privately-held VelosBio for $2.75B.
- VelosBio’s lead investigational candidate is VLS-101, an antibody-drug conjugate targeting ROR1, and is currently being evaluated in a Phase 1 and a Phase 2 trial for the treatment of patients with hematologic malignancies and solid tumors, respectively.
- The deal is expected to close by end of this year.
- https://seekingalpha.com/news/3631943-merck-scoops-up-velosbio-for-2_75b
Thursday, November 5, 2020
Merck scoops up VelosBio for $2.75B
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.